OKYO Pharma (STU:OK10) Net Margin %: 0.00% (As of Sep. 2025)


STU:OK10 OKYO Pharma Ltd STU:OK10
23 GF Score
Price €2.16
! 3 Warning Signs
View Full Analysis

What is OKYO Pharma Net Margin %?

OKYO Pharma STU:OK10 23 Net Margin % is 0.00% as of Sep. 2025. GuruFocus rates STU:OK10 with a GF Score™ of 23/100. The stock has 3 warning signs investors should review. Among 946 Biotechnology companies, OKYO Pharma ranks worse than 105708.14% on this metric.

Net margin is calculated as Net Income divided by its Revenue. OKYO Pharma's Net Income for the six months ended in Sep. 2025 was €-2.20 Mil. OKYO Pharma's Revenue for the six months ended in Sep. 2025 was €0.00 Mil. Therefore, OKYO Pharma's net margin for the quarter that ended in Sep. 2025 was 0.00%.

The historical rank and industry rank for OKYO Pharma's Net Margin % or its related term are showing as below:


STU:OK10's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -88.815
* Ranked among companies with meaningful Net Margin % only.

OKYO Pharma  (STU:OK10) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

OKYO Pharma Net Margin % Related Terms

OKYO Pharma Net Margin % Historical Data

* Premium members only.

The historical data trend for OKYO Pharma's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OKYO Pharma Net Margin % Chart

OKYO Pharma Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

OKYO Pharma Semi-Annual Data
Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

STU:OK10 vs SGMO, AARD, ANIX: Net Margin % Comparison

For the Biotechnology subindustry, OKYO Pharma's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OKYO Pharma Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OKYO Pharma's Net Margin % distribution charts can be found below:

* The bar in red indicates where OKYO Pharma's Net Margin % falls into.


STU:OK10
23GF Score
OKYO Pharma Ltd STU:OK10
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OKYO Pharma Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

OKYO Pharma's Net Margin for the fiscal year that ended in Mar. 2025 is calculated as

Net Margin=Net Income (A: Mar. 2025 )/Revenue (A: Mar. 2025 )
=-4.353/0
= %

OKYO Pharma's Net Margin for the quarter that ended in Sep. 2025 is calculated as

Net Margin=Net Income (Q: Sep. 2025 )/Revenue (Q: Sep. 2025 )
=-2.204/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
OKYO Pharma (STU:OK10) has a Net Margin % of 0.00% as of Sep. 2025. Net margin is the ratio of total net income to net sales. View historical data on OKYO Pharma and its competitors. According to the industry distribution chart, OKYO Pharma ranks #999999 out of 946 companies in the Biotechnology industry.
Is OKYO Pharma's Net Margin % too high?
OKYO Pharma's current Net Margin % is 0.00%. Based on the distribution chart, OKYO Pharma ranks #999999 out of 946 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, OKYO Pharma has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does OKYO Pharma's Net Margin % compare to SGMO and AARD?
According to the Biotechnology industry distribution chart, OKYO Pharma ranks #999999 out of 946 companies for Net Margin %. This places OKYO Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on OKYO Pharma and its competitors. OKYO Pharma's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OKYO Pharma stock overvalued right now?
OKYO Pharma (STU:OK10) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. OKYO Pharma's overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For OKYO Pharma (STU:OK10), the current Net Margin % is 0.00% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OKYO Pharma Business Description

Other Exchanges OKYO:USA
Address 14/15 Conduit Street, Floor 4, London, GBR, W1S 2XJ
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
23GF Score

Get the complete analysis for STU:OK10

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.16
Price